Dr. Bahar Ramezanpour

Chief Business Development Officer

Bahar Ramezanpour holds a Ph.D. in disruptive innovation by genetically modified technologies from the University of Amsterdam and Erasmus University of Rotterdam under the supervision of Prof. Ab Osterhaus and dr. Eric Claassen.

She joined HUB in 2017 with a background in MPA, infectious diseases and genetically modified vaccines. Prior to joining HUB, she served as Director Business Development at ViroNovative B.V. and Sovalacc B.V., biotechnology company and life sciences consultancy respectively. In these positions, she was responsible for all the aspects of business development, including out-licensing and alliance management. Furthermore, she has been involved in the start-up and growth of several business ventures in the life sciences sector.

May 27, 2020 Studying the development of ovarian cancer wi... Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of hig... read more
May 26, 2020 HUB Patient-Derived Organoids added to CrownB... San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid platform w... read more
May 13, 2020 Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species o... read more